Development and reliability testing of BRANT-MERQS-2A: A quality assessment tool for medication review type 2a reports.

IF 3.2 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Eline Tobback, Annouk Peeters, Nabileh Basir, Emilie Van Haver, Juno Quayhackx, Maja Brumer, Ronja Woltersdorf, Guido R Y De Meyer, Hans De Loof
{"title":"Development and reliability testing of BRANT-MERQS-2A: A quality assessment tool for medication review type 2a reports.","authors":"Eline Tobback, Annouk Peeters, Nabileh Basir, Emilie Van Haver, Juno Quayhackx, Maja Brumer, Ronja Woltersdorf, Guido R Y De Meyer, Hans De Loof","doi":"10.1007/s11096-026-02174-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Medication reviews (MRs) are increasingly implemented to optimize medication use and address drug-related problems in patients with complex pharmacotherapy, with medication review type 2a (MR2a) representing an intermediate format involving a pharmacist-led structured assessment with patient interview, based on clinical and medication data, without direct prescriber interaction. Despite their widespread implementation, systematic and operational approaches to evaluate the quality of MRs remain limited. In Belgium, Medication Review type 2a (MR2a) has been implemented in routine practice of community pharmacies since 2023, yet no validated instruments exist to evaluate the quality of written MR2a reports.</p><p><strong>Aim: </strong>This study aimed to adapt the existing BRANT-MERQS framework for the quality evaluation of MR2a reports and to assess the usability, reproducibility and reliability of the resulting tool (BRANT-MERQS-2A).</p><p><strong>Method: </strong>Relevant criteria were selected from the original BRANT-MERQS and expanded with criterion-specific instructions to form the BRANT-MERQS-2A. Initial testing involved two student assessors independently evaluating 98 MR2a reports, with interrater agreement (IRA) assessed using weighted Cohen's Kappa. In a subsequent extended testing phase, the same reports were assessed by 61 final-year pharmacy students, with three randomly selected students evaluating each MR2A report. Interrater reliability was evaluated using the Intraclass Correlation Coefficient (ICC) and Gwet's AC1. Assessment duration was recorded to evaluate feasibility.</p><p><strong>Results: </strong>Initial testing demonstrated strong IRA between the two student assessors. In the extended student cohort, agreement at the criterion level ranged from poor to moderate, with an overall ICC of 0.62, indicating moderate reliability. Criteria differed in discriminatory capacity, with some showing high absolute agreement but limited variability. Assessment time decreased over successive rounds, reflecting a learning effect and improved efficiency.</p><p><strong>Conclusion: </strong>The BRANT-MERQS-2A provides a feasible and structured approach for assessing the quality of MR2a reports. While variability at criterion level reflects the inherent complexity of MR2a, the tool demonstrates potential for self-and peer-assessment and offers a valuable foundation for further refinement and integration into routine quality monitoring.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"1967-1978"},"PeriodicalIF":3.2000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569523/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11096-026-02174-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Medication reviews (MRs) are increasingly implemented to optimize medication use and address drug-related problems in patients with complex pharmacotherapy, with medication review type 2a (MR2a) representing an intermediate format involving a pharmacist-led structured assessment with patient interview, based on clinical and medication data, without direct prescriber interaction. Despite their widespread implementation, systematic and operational approaches to evaluate the quality of MRs remain limited. In Belgium, Medication Review type 2a (MR2a) has been implemented in routine practice of community pharmacies since 2023, yet no validated instruments exist to evaluate the quality of written MR2a reports.

Aim: This study aimed to adapt the existing BRANT-MERQS framework for the quality evaluation of MR2a reports and to assess the usability, reproducibility and reliability of the resulting tool (BRANT-MERQS-2A).

Method: Relevant criteria were selected from the original BRANT-MERQS and expanded with criterion-specific instructions to form the BRANT-MERQS-2A. Initial testing involved two student assessors independently evaluating 98 MR2a reports, with interrater agreement (IRA) assessed using weighted Cohen's Kappa. In a subsequent extended testing phase, the same reports were assessed by 61 final-year pharmacy students, with three randomly selected students evaluating each MR2A report. Interrater reliability was evaluated using the Intraclass Correlation Coefficient (ICC) and Gwet's AC1. Assessment duration was recorded to evaluate feasibility.

Results: Initial testing demonstrated strong IRA between the two student assessors. In the extended student cohort, agreement at the criterion level ranged from poor to moderate, with an overall ICC of 0.62, indicating moderate reliability. Criteria differed in discriminatory capacity, with some showing high absolute agreement but limited variability. Assessment time decreased over successive rounds, reflecting a learning effect and improved efficiency.

Conclusion: The BRANT-MERQS-2A provides a feasible and structured approach for assessing the quality of MR2a reports. While variability at criterion level reflects the inherent complexity of MR2a, the tool demonstrates potential for self-and peer-assessment and offers a valuable foundation for further refinement and integration into routine quality monitoring.

BRANT-MERQS-2A: 2a型药物评审报告质量评估工具的开发与可靠性测试
药物审查(MRs)越来越多地用于优化药物使用和解决复杂药物治疗患者的药物相关问题,2a型药物审查(MR2a)代表一种中间形式,包括药剂师主导的结构化评估和患者访谈,基于临床和药物数据,没有处方者的直接互动。尽管它们得到了广泛的实施,但评估MRs质量的系统和可操作的方法仍然有限。在比利时,自2023年以来,药物审查类型2a (MR2a)已在社区药房的常规实践中实施,但没有经过验证的工具来评估书面MR2a报告的质量。目的:本研究旨在将现有的BRANT-MERQS框架用于MR2a报告的质量评估,并评估所得工具(BRANT-MERQS- 2a)的可用性、可重复性和可靠性。方法:从原BRANT-MERQS中选取相关标准,根据标准说明书进行扩充,形成BRANT-MERQS- 2a。最初的测试包括两名学生评估员独立评估98份MR2a报告,并使用加权科恩Kappa评估评分者之间的一致性(IRA)。在随后的扩展测试阶段,同样的报告由61名最后一年级的药学学生评估,随机选择三名学生评估每一份MR2A报告。用类内相关系数(Intraclass Correlation Coefficient, ICC)和Gwet’s AC1来评估组间信度。记录评估时间以评估可行性。结果:最初的测试显示两名学生评估者之间有很强的IRA。在扩展的学生队列中,标准水平的一致性范围从差到中等,总体ICC为0.62,表明信度中等。标准在区别对待能力方面有所不同,有些标准表现出高度的绝对一致性,但变异性有限。连续几轮的评估时间减少了,反映了学习效果和效率的提高。结论:BRANT-MERQS-2A为评估MR2a报告的质量提供了一种可行的、结构化的方法。虽然标准水平的可变性反映了MR2a的内在复杂性,但该工具显示了自我和同行评估的潜力,并为进一步改进和整合到常规质量监测中提供了有价值的基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
8.30%
发文量
131
审稿时长
4-8 weeks
期刊介绍: The International Journal of Clinical Pharmacy (IJCP) offers a platform for articles on research in Clinical Pharmacy, Pharmaceutical Care and related practice-oriented subjects in the pharmaceutical sciences. IJCP is a bi-monthly, international, peer-reviewed journal that publishes original research data, new ideas and discussions on pharmacotherapy and outcome research, clinical pharmacy, pharmacoepidemiology, pharmacoeconomics, the clinical use of medicines, medical devices and laboratory tests, information on medicines and medical devices information, pharmacy services research, medication management, other clinical aspects of pharmacy. IJCP publishes original Research articles, Review articles , Short research reports, Commentaries, book reviews, and Letters to the Editor. International Journal of Clinical Pharmacy is affiliated with the European Society of Clinical Pharmacy (ESCP). ESCP promotes practice and research in Clinical Pharmacy, especially in Europe. The general aim of the society is to advance education, practice and research in Clinical Pharmacy . Until 2010 the journal was called Pharmacy World & Science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书